##### 



Exhibit 10.3
 PATENT ASSIGNMENT AGREEMENT
 th Board System University OLGC Assignee
 W I T N E S S E T H:
 Appendix A
   Definitions.




---



##### 



Assignment.
  Confirmatory Assignment.
 Appendix B
 Intent of Assignment.
  Payment and Records.
 -2-




---



##### 



Appendix C
 -3-




---



##### 



FMV
  -4-




---



##### 



Term
  Notice
  Board of RegentsThe University of Texas System201 West 7th StreetAustin, Texas 78701ATTENTION: Office of General CounselFAX: (512) 499-4523PHONE: (512) 499-4462with copies to:
    
    University of Texas Medical Branch301 University Blvd., Route 0663Galveston, Texas 77555-0663ATTENTION: Director, TechnologyDevelopment CenterFAX: (409) 747-1441
 -5-




---



##### 



PHONE: (409) 747-0551or, in the case of Assignee to:
    
    OrthoLogic Corp.1275 West Washington StreetTempe, AZ 85281-1210ATTENTION: President and CEOFAX: 602-286-2808PHONE: 602-286-5500
 -6-




---



##### 



with a copy to:
    
    Quarles & Brady LLPOne Renaissance SquareTwo North Central AvenuePhoenix, AZ 85004ATTENTION: Steven P. EmerickFAX: 602-417-2980PHONE: 602-230-5517
  Texas Law.
  -7-




---



##### 



THE UNIVERSITY OF
TEXAS MEDICAL BRANCH, for itself and on behalf ofTHE BOARD OF REGENTS
OF THE UNIVERSITY OF TEXAS SYSTEM
    
    ORTHOLOGIC CORP.By:
    
    /s/ James C. Arie, Ph.D.
    
    By:
    
    /s/ James M. PuseyName:
    
    James C. Arie, Ph.D.
    
    Name: James M. PuseyTitle:
    
    Center for Technology Dv
    
    Title: President and CEODate:
    
    6/30/05
    
    Date: 6/23/05
 -8-




---



##### 



APPENDIX A
 Patent License Agreement
 (See Exhibit 10.1 to
Amendment No. 1 to the Companys Registration Statement on
Form S-4, filed with the SEC on July 14, 2004)




---



##### 



APPENDIX B
 ASSIGNMENT
  Appendix B1




---



##### 



By:
 Title
 Date:
 STATE OF TEXAS
    
    §§COUNTY OF
    
    
    
    §
 
  Notary Public in and forTHE STATE OF TEXASMy Commission Expires:
 2




---



##### 



Appendix B1
 Chrysalis Patent and Patent Applications Licensed from the University of Texas PATENT orPUBLICATIONNO. /ISSUE orAPP NO./
    
    
    
    PARENT NO./
    
    
    
    PUBLICATIONREF. NO.
    
    COUNTRY
    
    TITLE
    
    FILE DATE
    
    FILE TYPE
    
    FILE DATE
    
    INVENTOR(S)
    
    DATE
    
    STATUS3033.1000-000
    
    US
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    60/217,583
07/12/00
    
    PROV
    
    N/A
    
    Darrell H. Carney
    
    N/A
    
    Expired3033.1000-001
    
    US
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    09/904,090
07/12/01
    
    US
    
    60/217,583
7/12/00
    
    Darrell H. Carney
    
    20020061852A1
05/23/02
    
    Filed3033.1000-003
    
    PCT
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    PCT/US01/21944
07/12/01
    
    PCT
    
    60/217,583
07/12/00
    
    Darrell H. Carney
    
    WO02/004008
01/17/02
    
    Expired3033.1000-004
    
    Taiwan
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    90116938
07/11/01
    
    Taiwan
    
    60/217,583
07/12/00
    
    Darrell H. Carney
    
    
    
    Filed3033.1000-005
    
    Thailand
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    066866
07/11/01
    
    Thailand
    
    60/217,583
07/12/00
    
    Darrell H. Carney
    
    
    
    Filed3033.1000-007
    
    PCT
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    PCT/US02/01396
01/16/02
    
    PCT
    
    N/A
    
    Darrell H. Carney
    
    WO03/061689
07/31/03
    
    Filed3033.1000-008
    
    US
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    10/050,611
01/16/02
    
    CONT
    
    09/904,090
07/12/01
60/217,583
07/12/00
    
    Darrell H. Carney
    
    20020187933
12/12/02
    
    Filed3033.1000-009
    
    EPC
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    01957136.3
07/12/01
    
    EPC
    
    PCT/US01/21944
07/12/01
    
    Darrell H. Carney
    
    1253937B
09/10/03
    
    Granted3033.1000-010
    
    Japan
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    2002508462
07/12/01
    
    JAPAN
    
    PCT/US01/21944
07/12/01
    
    Darrell H. Carney
    
    
    
    Filed3033.1000-011
    
    Australia
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    2001278907
07/12/01
    
    Australia
    
    PCT/US01/21944
07/12/01
    
    Darrell H. Carney
    
    
    
    Filed3033.1000-012
    
    Canada
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    2415778
07/12/01
    
    Canada
    
    PCT/US01/21944
07/12/01
    
    Darrell H. Carney
    
    
    
    Filed3033.1000-013
    
    China
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    018154581
07/12/01
    
    China
    
    PCT/US01/21944
07/12/01
    
    Darrell H. Carney
    
    
    
    Filed




---



##### 



Chrysalis Patent and Patent Applications Licensed from the University of Texas PATENT orPUBLICATIONNO. /ISSUE orAPP NO./
    
    
    
    PARENT NO./
    
    
    
    PUBLICATIONREF. NO.
    
    COUNTRY
    
    TITLE
    
    FILE DATE
    
    FILE TYPE
    
    FILE DATE
    
    INVENTOR(S)
    
    DATE
    
    STATUS3033.1000-014
    
    Austria
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    01957136.3
07/12/01
    
    EPC
    
    PCT/US01/21944
07/12/01
    
    Darrell H. Carney
    
    1253937
09/10/03
    
    Granted3033.1000-015
    
    Belgium
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    01957136.3
07/12/01
    
    EPC
    
    PCT/US01/21944
07/12/01
    
    Darrell H. Carney
    
    1253937
09/10/03
    
    Granted3033.1000-016
    
    France
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    01957136.3
07/12/01
    
    EPC
    
    PCT/US01/21944
07/12/01
    
    Darrell H. Carney
    
    1253937
09/10/03
    
    Granted3033.1000-017
    
    Germany
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    01957136.3
07/12/01
    
    EPC
    
    PCT/US01/21944
07/12/01
    
    Darrell H. Carney
    
    60100740.9-08
09/10/03
    
    Granted3033.1000-018
    
    Great
Britain
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    01957136.3
07/12/01
    
    EPC
    
    PCT/US01/21944
07/12/01
    
    Darrell H. Carney
    
    1253937
09/10/03
    
    Granted3033.1000-019
    
    Italy
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    01957136.3
07/12/01
    
    EPC
    
    PCT/US01/21944
07/12/01
    
    Darrell H. Carney
    
    1253937
09/10/03
    
    Granted3033.1000-020
    
    Netherlands
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    01957136.3
07/12/01
    
    EPC
    
    PCT/US01/21944
07/12/01
    
    Darrell H. Carney
    
    1253937
09/10/03
    
    Granted3033.1000-021
    
    Switzerland
    
    METHODS OF THERAPY WITH THROMBIN
DERIVED PEPTIDES
    
    01957136.3
07/12/01
    
    EPC
    
    PCT/US01/21944
07/12/01
    
    Darrell H. Carney
    
    1253937
09/10/03
    
    Granted3033.1001-000*
    
    US
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    06/925,201
10/31/86
    
    US
    
    -
    
    Darrell H. Carney,
et al.
    
    5,352,664
10/04/94
    
    Issued3033.1001-001*
    
    US
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    08/007,173
01/21/93
    
    DIV
    
    06/925,201
10/31/86
    
    Darrell H. Carney,
et al.
    
    5,500,412
03/19/96
    
    Issued3033.1001-002*
    
    US
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    08/538,504
09/29/95
    
    CONT
    
    06/925,201
10/31/86
    
    Darrell H. Carney,
et al.
    
    6,627,731
09/30/03
    
    Issued3033.1001-003*
    
    US
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    09/630,484
08/02/00
    
    CIP
    
    08/538,504
09/29/95
    
    Darrell H. Carney,
et al.
    
    
    
    Filed3033.1001-004*
    
    US
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    09/631,137
08/02/00
    
    CIP
    
    08/538,504
09/29/95
    
    Darrell H. Carney,
et al.
    
    6,630,572
10/07/03
    
    Issued3033.1001-008*
    
    EPC
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    87907652.9
10/30/87
    
    EPC
    
    PCT/US87/02882
10/30/87
    
    Darrell H. Carney,
et al.
    
    0328552
05/05/94
    
    Issued




---



##### 



Chrysalis Patent and Patent Applications Licensed from the University of Texas PATENT orPUBLICATIONNO. /ISSUE orAPP NO./
    
    
    
    PARENT NO./
    
    
    
    PUBLICATIONREF. NO.
    
    COUNTRY
    
    TITLE
    
    FILE DATE
    
    FILE TYPE
    
    FILE DATE
    
    INVENTOR(S)
    
    DATE
    
    STATUS3033.1001-009*
    
    Switzerland
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    879076529
10/30/87
    
    Switzerland
    
    87907652.9
10/30/87
    
    Darrell H. Carney,
et al.
    
    0328552
05/05/94
    
    Issued3033.1001-010*
    
    France
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    879076529
10/30/87
    
    France
    
    87907652.9
10/30/87
    
    Darrell H. Carney,
et al.
    
    0328552
05/05/94
    
    Issued3033.1001-011*
    
    Great
Britain
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    879076529
10/30/87
    
    Great
Britain
    
    87907652.9
10/30/87
    
    Darrell H. Carney,
et al.
    
    0328552
05/05/94
    
    Issued3033.1001-012*
    
    Italy
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    879076529
10/30/87
    
    Italy
    
    87907652.9
10/30/87
    
    Darrell H. Carney,
et al.
    
    0328552
05/05/94
    
    Issued3033.1001-013*
    
    Netherlands
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    879076529
10/30/87
    
    Nether-lands
    
    87907652.9
10/30/87
    
    Darrell H. Carney,
et al.
    
    0328552
05/05/94
    
    Issued3033.1001-014*
    
    Germany
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    879076529
10/30/87
    
    Germany
    
    87907652.9
10/30/87
    
    Darrell H. Carney,
et al.
    
    0328552
05/05/94
    
    Issued3033.1001-015*
    
    Sweden
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    879076529
10/30/87
    
    Sweden
    
    87907652.9
10/30/87
    
    Darrell H. Carney,
et al.
    
    0328552
05/05/94
    
    Issued3033.1001-016*
    
    Canada
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    595965
04/06/89
    
    Canada
    
    06/925,201
04/06/89
    
    Darrell H. Carney,
et al.
    
    1341108
10/30/00
    
    Issued3033.1001-017*
    
    Japan
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    5070531987
10/30/87
    
    Japan
    
    PCT/US87/02882
10/30/87
    
    Darrell H. Carney,
et al.
    
    3054150
04/07/00
    
    Issued3033.1001-018*
    
    Belgium
    
    THROMBIN DERIVED POLYPEPTIDES:
COMPOSITIONS AND METHODS FOR USE
    
    879076529
10/30/87
    
    Belgium
    
    87907652.9
10/30/87
    
    Darrell H. Carney,
et al.
    
    0328552
05/05/94
    
    Issued3033.1002-000
    
    US
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    60/219,300
07/19/00
    
    PROV
    
    N/A
    
    Darrell H. Carney,
et al.
    
    N/A
    
    Expired3033.1002-001
    
    US
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    09/909,122
07/19/01
    
    CIP
    
    60/219,300
07/19/00
    
    Darrell H. Carney,
et al.
    
    20020128202A1
09/12/02
    
    Filed3033.1002-003
    
    PCT
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    PCT/US01/22641
07/18/01
    
    PCT
    
    60/219,300
07/19/00
    
    Darrell H. Carney,
et al.
    
    WO02/05836
01/24/02
    
    Expired3033.1002-004
    
    US
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    10/050,692
01/16/02
    
    CONT
    
    09/909,122
07/19/01
60/219,300
07/19/00
    
    Darrell H. Carney,
et al.
    
    20020182205A1
12/5/02
    
    Filed




---



##### 



Chrysalis Patent and Patent Applications Licensed from the University of Texas PATENT orPUBLICATIONNO. /ISSUE orAPP NO./
    
    
    
    PARENT NO./
    
    
    
    PUBLICATIONREF. NO.
    
    COUNTRY
    
    TITLE
    
    FILE DATE
    
    FILE TYPE
    
    FILE DATE
    
    INVENTOR(S)
    
    DATE
    
    STATUS3033.1002-006
    
    PCT
    
    STIMULATION OF BONE GROWTH AND
CARTILAGE FORMATION WITH THROMBIN
PEPTIDE DERIVATIVES
    
    PCT/US02/01451
01/17/02
    
    PCT
    
    N/A
    
    Darrell H. Carney,
et al.
    
    WO03/061690
4/16/03
    
    Filed3033.1002-007
    
    EPC
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    EPC
    
    PCT/US01/22641
07/18/01
    
    Darrell H. Carney,
et al.
    
    1301196B
11/26/03
    
    Granted3033.1002-008
    
    Japan
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    2002511768
07/18/01
    
    Japan
    
    PCT/US01/22641
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Filed3033.1002-009
    
    Australia
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    20021276977
07/18/01
    
    Australia
    
    PCT/US01/22641
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Filed3033.1002-010
    
    Canada
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    2416487
07/18/01
    
    Canada
    
    PCT/US01/22641
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Filed3033.1002-011
    
    China
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    018158226
07/18/01
    
    China
    
    PCT/US01/22641
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Filed3033.1002-012
    
    Hong Kong
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    031074300
10/15/03
    
    Hong Kong
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    1055250A
01/02/04
    
    Filed3033.1002-013
    
    Austria
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Austria
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-014
    
    Belgium
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Belgium
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-015
    
    Cyprus
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Cyprus
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-016
    
    Denmark
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Denmark
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-017
    
    Finland
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Finland
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-018
    
    France
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    France
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-019
    
    Germany
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Germany
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    60101339.5-08
11/26/03
    
    Granted




---



##### 



Chrysalis Patent and Patent Applications Licensed from the University of Texas PATENT orPUBLICATIONNO. /ISSUE orAPP NO./
    
    
    
    PARENT NO./
    
    
    
    PUBLICATIONREF. NO.
    
    COUNTRY
    
    TITLE
    
    FILE DATE
    
    FILE TYPE
    
    FILE DATE
    
    INVENTOR(S)
    
    DATE
    
    STATUS3033.1002-020
    
    Great Britain
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Great Britain
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-021
    
    Greece
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Greece
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-022
    
    Ireland
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Ireland
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-023
    
    Italy
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Italy
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-024
    
    Luxembourg
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Luxembourg
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-025
    
    Monaco
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Monaco
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-026
    
    Netherlands
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Netherlands
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-027
    
    Portugal
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Portugal
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-028
    
    Spain
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Spain
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-029
    
    Sweden
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Sweden
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-030
    
    Switzerland
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Switzerland
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1002-031
    
    Turkey
    
    STIMULATION OF BONE GROWTH WITH
THROMBIN PEPTIDE DERIVATIVES
    
    01954752.0
07/18/01
    
    Turkey
    
    EPC 01954752.0
07/18/01
    
    Darrell H. Carney,
et al.
    
    
    
    Disclosure3033.1003-000
    
    US
    
    STIMULATION OF CARTILAGE GROWTH
WITH AGONISTS OF THE
NONPROTEOLYTICALLY ACTIVATED
THROMBIN RECEPTOR
    
    60/219,800
07/20/00
    
    PROV
    
    N/A
    
    Darrell H. Carney,
et al.
    
    N/A
    
    Expired3033.1003-001
    
    US
    
    STIMULATION OF CARTILAGE GROWTH
WITH AGONISTS OF THE
NONPROTEOLYTICALLY ACTIVATED
THROMBIN RECEPTOR
    
    09/909,348
07/19/01
    
    CIP
    
    60/219,800
07/20/00
    
    Darrell H. Carney,
et al.
    
    20020042373A1
04/11/02
    
    Filed




---



##### 



Chrysalis Patent and Patent Applications Licensed from the University of Texas PATENT orPUBLICATIONNO. /ISSUE orAPP NO./
    
    
    
    PARENT NO./
    
    
    
    PUBLICATIONREF. NO.
    
    COUNTRY
    
    TITLE
    
    FILE DATE
    
    FILE TYPE
    
    FILE DATE
    
    INVENTOR(S)
    
    DATE
    
    STATUS3033.1003-003
    
    PCT
    
    STIMULATION OF CARTILAGE GROWTH
WITH AGONISTS OF THE
NONPROTEOLYTICALLY ACTIVATED
THROMBIN RECEPTOR
    
    PCT/US01/22668
07/19/01
    
    PCT
    
    09/909,348
07/19/01
60/219,800
07/20/00
    
    Darrell H. Carney,
et al.
    
    WO02/07748
01/31/02
    
    Expired3033.1003-004
    
    US
    
    STIMULATION OF CARTILAGE GROWTH
WITH AGONISTS OF THE
NONPROTEOLYTICALLY ACTIVATED
THROMBIN RECEPTOR
    
    10/050,688
01/16/02
    
    CONT
    
    09/904,090
07/12/01
60/217,583
07/12/00
    
    Darrell H. Carney,
et al.
    

    20020198154A1
12/26/02

    
    Filed3033.1003-005
    
    EPC
    
    STIMULATION OF CARTILAGE GROWTH
WITH AGONISTS OF THE
NONPROTEOLYTICALLY ACTIVATED
THROMBIN RECEPTOR
    
    01952846.2
07/19/01
    
    EPC
    
    PCT/US01/22668
07/19/01
    
    Darrell H. Carney,
et al.
    
    
    1259598A
11/27/02
    
    
    Allowed3033.1003-006
    
    Japan
    
    STIMULATION OF CARTILAGE GROWTH
WITH AGONISTS OF THE
NONPROTEOLYTICALLY ACTIVATED
THROMBIN RECEPTOR
    
    2002513481
07/19/01
    
    Japan
    
    PCT/US01/22668
07/19/01
    
    Darrell H. Carney,
et al.
    
    
    
    
    
    Filed3033.1003-007
    
    Australia
    
    STIMULATION OF CARTILAGE GROWTH
WITH AGONISTS OF THE
NONPROTEOLYTICALLY ACTIVATED
THROMBIN RECEPTOR
    
    2001273561
07/19/01
    
    Australia
    
    PCT/US01/22668
07/19/01
    
    Darrell H. Carney,
et al.
    
    
    
    
    
    Filed3033.1003-008
    
    Canada
    
    STIMULATION OF CARTILAGE GROWTH
WITH AGONISTS OF THE
NONPROTEOLYTICALLY ACTIVATED
THROMBIN RECEPTOR
    
    2416404
07/19/01
    
    Canada
    
    PCT/US01/22668
07/19/01
    
    Darrell H. Carney,
et al.
    
    
    
    
    
    Filed3033.1003-009
    
    China
    
    STIMULATION OF CARTILAGE GROWTH
WITH AGONISTS OF THE
NONPROTEOLYTICALLY ACTIVATED
THROMBIN RECEPTOR
    
    018158218
07/19/01
    
    China
    
    PCT/US01/22668
07/19/01
    
    Darrell H. Carney,
et al.
    
    CN1458974
11/26/03
    
    Filed3033.1003-010
    
    Hong Kong
    
    STIMULATION OF CARTILAGE GROWTH
WITH AGONISTS OF THE
NONPROTEOLYTICALLY ACTIVATED
THROMBIN RECEPTOR
    
    03103723.5
05/27/03
    
    Hong Kong
    
    PCT/US01/22668
07/19/01
    
    Darrell H. Carney,
et al.
    
    
    1052367
    
    
    Filed3033.1004-000
    
    US
    
    THROMBIN PEPTIDE DERIVATIVE DIMERS
    
    60/393,579
07/02/02
    
    PROV
    
    N/A
    
    Darrell H. Carney,
et al.
    
    
    
    
    
    Filed3033.1004-002
    
    PCT
    
    THROMBIN PEPTIDE DERIVATIVE DIMERS
    
    PCT/US03/20626
    
    PCT
    
    N/A
    
    Darrell H. Carney,
et al.
    
    WO2004/005317
01/15/04
    
    Filed3033.1006-000
    
    US
    
    THROMBIN PEPTIDE DERIVATIVES
    
    60/393,580
07/02/02
    
    PROV
    
    N/A
    
    Darrell H. Carney,
et al.
    
    
    
    
    
    Filed3033.1006-002
    
    PCT
    
    THROMBIN PEPTIDE DERIVATIVES
    
    PCT/US03/20635
07/01/03
    
    PCT
    
    60/393,580
0/02/02
    
    Darrell H. Carney,
et al.
    
    WO2004/014937
02/19/04
    
    Filed3033.1007-000
    
    US
    
    DIMERS OF THROMBIN
POLYPEPTIDE FRAGMENTS
    
    
    
    Disclosure
    
    N/A
    
    N/A




---



##### 



Chrysalis Patent and Patent Applications Licensed from the University of Texas PATENT orPUBLICATIONNO. /ISSUE orAPP NO./
    
    
    
    PARENT NO./
    
    
    
    PUBLICATIONREF. NO.
    
    COUNTRY
    
    TITLE
    
    FILE DATE
    
    FILE TYPE
    
    FILE DATE
    
    INVENTOR(S)
    
    DATE
    
    STATUS3033.1008-000
    
    US
    
    METHOD FOR PROMOTING HEALING OF
CHRONIC DERMAL ULCERS
    
    60/308,198
07/27/01
    
    PROV
    
    N/A
    
    Darrell H. Carney
    
    N/A
    
    Expired3033.1008-002
    
    PCT
    
    METHOD FOR PROMOTING HEALING OF
CHRONIC ULCERS
    
    PCT/US02/01151
01/16/02
    
    PCT
    
    60/308,198
07/27/01
    
    Darrell H. Carney
    
    WO03/013569
2/20/03
    
    Filed3033.1008-003
    
    Australia
    
    METHOD FOR PROMOTING HEALING OF
CHRONIC ULCERS
    
    
    
    Australia
    
    PCT/US02/01151
01/16/02
    
    Darrell H. Carney
    
    
    
    Filed3033.1008-004
    
    Canada
    
    METHOD FOR PROMOTING HEALING OF
CHRONIC ULCERS
    
    
    
    Canada
    
    PCT/US02/01151
01/16/02
    
    Darrell H. Carney
    
    
    
    Filed3033.1008-005
    
    China P.R.
    
    METHOD FOR PROMOTING HEALING OF
CHRONIC ULCERS
    
    
    
    China P.R.
    
    PCT/US02/01151
01/16/02
    
    Darrell H. Carney
    
    
    
    Disclosure3033.1008-006
    
    EPC
    
    METHOD FOR PROMOTING HEALING OF
CHRONIC ULCERS
    
    02703130.1
01/16/02
    
    EPC
    
    PCT/US02/01151
01/16/02
    
    Darrell H. Carney
    
    
    
    Filed3033.1008-007
    
    Japan
    
    METHOD FOR PROMOTING HEALING OF
CHRONIC ULCERS
    
    
    
    Japan
    
    PCT/US02/01151
01/16/02
    
    Darrell H. Carney
    
    
    
    Filed3033.1008-007
    
    US
    
    METHOD FOR PROMOTING HEALING OF
CHRONIC ULCERS
    
    10/766,752
01/27/04
    
    CON
    
    PCT/US02/01151
01/16/02
    
    Darrell H. Carney
    
    
    
    Filed3033.1009-000
    
    US
    
    PHARMACEUTICAL COMPOSITION FOR
THROMBIN PEPTIDE DERIVATIVES
    
    60/533,730
12/31/03
    
    PROV
    
    60/533,730
12/31/03
    
    Darrell H. Carney,
et al.
    
    
    
    Filed
 *Co-owned by Pfizer, with interest exclusively licensed to The University of
Texas through original Agreement with Monsanto (Monsanto Pharmaceuticals was
acquired by Pharmacia, which was subsequently acquired by Pfizer)




---



##### 



APPENDIX C
 Form of Security Agreement (Patents)
 SECURITY AGREEMENT
(Patents) This Security Agreement dated as of [      ] (this Agreement), is
made by [ASSIGNEE], a [STATE] corporation (the Debtor), in favor of the Board
of Regents of the University of Texas System, an agency of the State of Texas
(the Secured Party) through its component institution, The University of
Texas Medical Branch at Galveston (the University). INTRODUCTION Reference is made to that certain Patent Assignment Agreement dated as of
[       ] (as amended, restated, modified, or supplemented from
time to time, the Patent Assignment Agreement), between the Secured Party and
the Debtor. The Patent Assignment Agreement, among other things, contemplates
a possibility of the grant of a security interest in Assignees interest
therein upon the occurrence of certain events. NOW THEREFORE, in consideration of the foregoing and for other good and
valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, the Debtor agrees with the Secured Party as follows: Section 1. DEFINITIONS 1.1 Terms defined above and elsewhere in this Agreement shall have their
specified meanings. Capitalized terms used herein but not defined herein shall
have the meanings specified in the Patent Assignment Agreement. Capitalized
terms that are neither defined herein nor in the Patent Assignment Agreement
shall have the meanings specified in Article 9 of the UCC. 1.2 The following terms shall have the following meanings: Carney means Darrel H. Carney, Ph.D. Collateral means any and all of the Debtors present and future rights
in and to the Patent Rights assigned to Debtor under the Patent Assignment
Agreement and the inventions claimed therein, and all proceeds thereof. Event of Default means a default of the Debtor in its payment
obligations under the Patent Assignment Agreement. Patent License Documents means the Patent Assignment Agreement, and any
other documents made or delivered from time to time in connection therewith,
but shall not include that certain Patent License Agreement dated as of
        , 2004 between the Secured Party and the Debtor.




---



##### 



Secured Obligations means (a) all principal, interest, fees,
reimbursements, indemnifications, and other amounts now or hereafter owed by
the Debtor to the Secured Party under this Agreement, the Patent Assignment
Agreement, and the other Patent Assignment Documents; and (b) any increases,
extensions, and rearrangements of the foregoing obligations under any
amendments, supplements, and other modifications of the agreements creating the
foregoing obligations. UCC means the Uniform Commercial Code as in effect on the date hereof in
the State of Texas. Section 2. COLLATERAL; GRANT 2.1 Grant of Security Interest. The Debtor hereby grants to the Secured
Party a security interest in all of the Debtors present and future right,
title, and interest in and to the Collateral to secure the payment and
performance of the Secured Obligations. To the extent that the Collateral is
not subject to the UCC, the Debtor collaterally assigns all of the Debtors
right, title, and interest in and to such Collateral to the Secured Party to
secure the payment and performance of the Secured Obligations to the full
extent that such a collateral assignment is possible under the relevant law. 2.2 Debtors Remain Liable. Anything herein to the contrary
notwithstanding: (a) the Debtor shall remain liable under any contracts and
agreements included in the Collateral of the Debtor to the extent set forth
therein to perform the Debtors obligations thereunder to the same extent as if
this Agreement had not been executed; (b) the exercise by the Secured Party of
any rights hereunder shall not release the Debtor from any obligations under
any contracts and agreements included in the Collateral of the Debtor; and (c)
the Secured Party shall not have any obligation under any contracts and
agreements included in the Collateral of the Debtor by reason of this
Agreement, nor shall the Secured Party be obligated to perform or fulfill any
of the obligations of the Debtor thereunder, including any obligation to make
any inquiry as to the nature or sufficiency of any payment that the Debtor may
be entitled to receive thereunder, to present or file any claim, or to take any
action to collect or enforce any claim for payment thereunder. 2.3 Financing Statements. The Debtor represents and warrants to and
agrees with the Secured Party as follows: (a) As of the date of this Agreement, the true and correct name of the
Debtor as listed on the Debtors certificate of incorporation is the name
specified for the Debtor on the signature page of this Agreement. The Debtor
has had no prior names other than [     ]. The Debtor has not used
and does not use any trade names other than
[     ]. As of the date
of this Agreement, the Debtor is organized under the laws of the State of
[     ]. Without advance written notice to the Secured Party and
reasonable opportunity for the Secured Party to take action to protect the
Secured Partys interests hereunder, the Debtor shall not change its name,
reincorporate or otherwise reorganize, or change its jurisdiction of
organization.




---



##### 



(b) The Debtor authorizes the Secured Party to file one or more financing
statements, or other documents describing any or all of the Collateral in any
filing or recording office. Section 3. REMEDIES 3.1 General Remedies. During the existence of an Event of Default, the
Secured Party may, at the Secured Partys option, exercise one or more of the
following remedies: (a) To the extent permitted by law, the Secured Party may exercise all the
rights and remedies of a secured party under the UCC. (b) The Secured Party may prosecute actions in equity or at law for the
specific performance of any covenant or agreement herein contained or in aid of
the execution of any power herein granted or for the enforcement of any other
appropriate legal or equitable remedy. (c) The Secured Party may instruct any obligors owing payments to the
Debtor with respect to the Collateral, including royalty payments, to make all
such payments directly to the Secured Party. (d) The Secured Party may foreclose on any Collateral in any manner
permitted by the courts of or in the State of Texas or the state in which any
Collateral is located. If the Secured Party should institute a suit for the
collection of the Secured Obligations and for foreclosure under this Agreement,
the Secured Party may at any time before the entry of a final judgment dismiss
the same, and take any other action permitted by this Agreement. (e) To the extent permitted by law, the Secured Party may exercise all the
foreclosure rights and remedies of a secured party under the UCC. In
connection therewith, the Secured Party may sell any Collateral at public or
private sale, at the office of the Secured Party or elsewhere, for cash or
credit and upon such other terms as the Secured Party deems commercially
reasonable. The Secured Party may sell any Collateral at one or more sales,
and the security interest granted hereunder shall remain in effect as to the
unsold portion of the Collateral. The Secured Party shall not be obligated to
make any sale of Collateral regardless of notice of sale having been given.
The Secured Party may adjourn any sale by announcement at the time and place
fixed therefor, and such sale may, without further notice, be made at the time
and place to which it was adjourned. In the event that any sale hereunder is
not completed or is defective in the opinion of the Secured Party, the Secured
Party shall have the right to cause subsequent sales to be made hereunder. Any
statements of fact or other recitals made in any bill of sale, assignment, or
other document representing any sale hereunder, including statements relating
to the occurrence of an Event of Default, acceleration of the Secured
Obligations, notice of the sale, the time, place, and terms of the sale, and
other actions taken by the Secured Party in relation to the sale may be
conclusively relied upon by the purchaser at any sale hereunder. The Secured
Party may delegate to any agent the performance of any acts in connection with
any sale hereunder, including the sending of notices and the conduct of the
sale.




---



##### 



(f) All costs and expenses incurred by the Secured Party in enforcement or
preservation of its rights under this Agreement, including attorneys fees and
out-of-pocket expenses, shall be reimbursed by the Debtor to the Secured Party
on demand. 3.2 Application of Proceeds. (a) Unless otherwise specified herein, any cash proceeds received by the
Secured Party from the sale of, collection of, or other realization upon any
part of the Collateral or any other amounts received by the Secured Party
hereunder may be, at the reasonable discretion of the Secured Party (i) held by
the Secured Party as cash collateral for the Secured Obligations or (ii)
applied to the Secured Obligations. (b) Amounts applied to the Secured Obligations shall be applied in the
following order: First, to the payment of the costs and expenses of exercising the
Secured Partys rights hereunder, whether expressly provided for herein
or otherwise; and Second, to the payment of the Secured Obligations in the order set
forth by the Secured Party. Any surplus cash collateral or cash proceeds held by the Secured Party after
payment in full of the Secured Obligations and the termination of any
commitments of the Secured Party to any Debtor shall be paid over to the Debtor
or to whomever may be lawfully entitled to receive such surplus. 3.3 Remedies Cumulative. The Secured Partys remedies under this
Agreement and the Patent License Documents shall be cumulative, and no delay in
enforcing this Agreement and the Patent License Documents shall act as a waiver
of the Secured Partys rights hereunder or thereunder. Section 4. GENERAL 4.1 Choice of Law. THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE LAWS OF THE UNITED STATES OF AMERICA AND THE STATE OF
TEXAS. 4.2 Notice. All notices and other communications from the Secured Party
to the Debtor provide for in this Agreement shall be delivered in the manner
and to the addresses set forth in the Patent Assignment Agreement. 4.3 General. If any provision in this Agreement is held to be
unenforceable, such provision shall be severed and the remaining provisions
shall remain in full force and effect. All representations, warranties, and
covenants of the Debtor in this Agreement shall survive the execution of this
Agreement and the other Patent License Documents. If a due date for an amount
payable is not specified in this Agreement, the due date shall be the date on
which the Secured Party demands payment therefor. The provisions of this
Agreement may be waived or




---



##### 



amended only in a writing signed by the party against whom enforcement is
sought. This Agreement shall bind and inure to the benefit of the Debtor and
the Secured Party and their respective successors and assigns. The Debtor may
not assign its rights or delegate its duties under this Agreement; provided,
that Debtor may assign its rights and delegate its duties to the assignee of
Debtors rights under the Patent Assignment Agreement in connection with any
assignment permitted thereunder, so long as such assignee assumes and agrees to
perform all of Debtors obligations hereunder. This Agreement may be executed
in multiple counterparts each of which shall constitute one and the same
agreement. [SIGNATURE PAGE FOLLOWS]




---



##### 



THIS WRITTEN AGREEMENT AND THE OTHER PATENT LICENSE DOCUMENTS REPRESENT THE
FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF
PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE
ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES. EXECUTED as of the date first above written. [ASSIGNEE]By:Name:Title:THE BOARD OF REGENTS OF THE  UNIVERSITY OF TEXAS SYSTEMBY:
    
    THE UNIVERSITY OF TEXAS MEDICAL  BRANCHBy:Name:Title: